Chelsea responds to FDA; Northera clock to soon tick again
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics kept its word that it would quickly address certain technical deficiencies the FDA identified last month with the company's resubmitted new drug application (NDA) for Northera (droxidopa) – announcing on 14 August the firm had indeed provided regulators with additional information.